A vaginal mesh implant made by one of the world’s biggest pharmaceutical firms was launched despite the company being warned it could shrink and harden inside the body, company documents reveal. Despite this risk, the Prolift implant was made available in 2005 and marketed for seven years. But the trial found higher complication rates for mesh surgery, with more than one in 10 patients experiencing complications linked to the mesh implants. In June 2012, Johnson & Johnson voluntarily withdrew Prolift from the market, after being ordered by the FDA to carry out further testing. Asked about the issues raised by the documents, Johnson & Johnson declined to comment.

Source: The Guardian November 27, 2018 17:34 UTC